Carl Zeiss Meditec AG has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Carl Zeiss Meditec AG's Cash Ratio or its related term are showing as below:
XSWX:AFX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.05 Max: 0.09
Current: 0.05
During the past 13 years, Carl Zeiss Meditec AG's highest Cash Ratio was 0.09. The lowest was 0.01. And the median was 0.05.
XSWX:AFX's Cash Ratio is ranked worse than 95.72% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs XSWX:AFX: 0.05
Carl Zeiss Meditec AG (XSWX:AFX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:AFX vs ISRG, BDX, MDLN: Cash Ratio Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG (XSWX:AFX) has a Cash Ratio of 0.00 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Carl Zeiss Meditec AG and its competitors. Over the past decade, Carl Zeiss Meditec AG's Cash Ratio has ranged from 0.01 to 0.09. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #806 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 95.7%.
Is Carl Zeiss Meditec AG's Cash Ratio too high?
Carl Zeiss Meditec AG's current Cash Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.09. Based on the distribution chart, Carl Zeiss Meditec AG ranks #806 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Carl Zeiss Meditec AG has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Cash Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #806 out of 842 companies for Cash Ratio. This places Carl Zeiss Meditec AG in the lower half of its industry. The industry median Cash Ratio is 0.97. Historically, Carl Zeiss Meditec AG's own Cash Ratio has ranged from 0.01 to 0.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current Cash Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF64.87, compared to a current price of CHF25.86 — trading 60.1% below its estimated fair value. The current Cash Ratio is 0.00. Carl Zeiss Meditec AG's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Cash Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF25.86 is trading 60.1% below its estimated GF Value™ of CHF64.87.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
Cash Ratio: 0.00
GF Value™: CHF64.87 vs. price of CHF25.86 (60.1% below fair value)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
69GF Score
Get the complete analysis for XSWX:AFX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
